Exercise no. 313 Tirzepatide (Mounjaro°) in type 2 diabetes: no better than a GLP-1 agonist

An important objective of treatment for type 2 diabetes is to prevent or delay the complications associated with the disease, in particular cardiovascular complications. When dietary measures combined with regular exercise are considered insufficiently effective, metformin monotherapy is the first-choice pharmacological treatment. It appears to prevent certain complications and to extend survival, and its adverse effects are usually acceptable. When metformin is insufficiently effective or cannot be used, a glucagon-like peptide-1 (GLP-1) agonist such as liraglutide, dulaglutide or semaglutide is an option, especially when the risk of cardiovascular events is high, or when weight loss is an important objective.